# Arteriosclerosis; Hypercholesterolaemia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/arteriosclerosis-hypercholesterolaemia

> 2 upcoming FDA catalysts in arteriosclerosis; Hypercholesterolaemia: Lipfendra (enlicitide decanoate, MRK) on Nov 2029 to Feb 2030 (topline data readout); Lipfendra (enlicitide decanoate, MRK) on November 2029 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2029 to Feb 2030 | [Lipfendra (enlicitide decanoate) topline data readout](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Arteriosclerosis; Hypercholesterolaemia | scheduled | "NCT06008756 (Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06008756)) |
| November 2029 | [Lipfendra (enlicitide decanoate) primary completion](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Arteriosclerosis; Hypercholesterolaemia | scheduled | "NCT06008756 (Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06008756)) |

## Drugs

- [Lipfendra (enlicitide decanoate)](https://sec-api.dev/pdufa/enlicitide-decanoate) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/arteriosclerosis-hypercholesterolaemia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Arteriosclerosis; Hypercholesterolaemia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/arteriosclerosis-hypercholesterolaemia

```bibtex
@misc{secapidev_indications_arteriosclerosis_hypercholesterolaemia_20261116,
  title        = {Arteriosclerosis; Hypercholesterolaemia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/arteriosclerosis-hypercholesterolaemia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_arteriosclerosis_hypercholesterolaemia_20261116","title":"Arteriosclerosis; Hypercholesterolaemia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/arteriosclerosis-hypercholesterolaemia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
